Cutting Edge: Role of MASP-3 in the Physiological Activation of Factor D of the Alternative Complement Pathway. 2019

Manabu Hayashi, and Takeshi Machida, and Yumi Ishida, and Yusuke Ogata, and Tomoko Omori, and Mika Takasumi, and Yuichi Endo, and Toshiyuki Suzuki, and Masayuki Sekimata, and Yoshimi Homma, and Masahito Ikawa, and Hiromasa Ohira, and Teizo Fujita, and Hideharu Sekine
Department of Immunology, Fukushima Medical University School of Medicine, Fukushima City, Fukushima 960-1295, Japan.

The complement system, a part of the innate immune system, can be activated via three different pathways. In the alternative pathway, a factor D (FD) plays essential roles in both the initiation and the amplification loop and circulates as an active form. Mannose-binding lectin-associated serine proteases (MASPs) are key enzymes of the lectin pathway, and MASP-1 and/or MASP-3 are reported to be involved in the activation of FD. In the current study, we generated mice monospecifically deficient for MASP-1 or MASP-3 and found that the sera of the MASP-1-deficient mice lacked lectin pathway activity, but those of the MASP-3-deficient mice lacked alternative pathway activity with a zymogen FD. Furthermore, the results indicate that MASP-3 but not MASP-1 activates the zymogen FD under physiological conditions and MASP-3 circulates predominantly as an active form. Therefore, our study illustrates that, in mice, MASP-3 orchestrates the overall complement reaction through the activation of FD.

UI MeSH Term Description Entries
D007107 Immune System The body's defense mechanism against foreign organisms or substances and deviant native cells. It includes the humoral immune response and the cell-mediated response and consists of a complex of interrelated cellular, molecular, and genetic components. Immune Systems,System, Immune,Systems, Immune
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D011416 Complement Factor D A serum protein which is important in the ALTERNATIVE COMPLEMENT ACTIVATION PATHWAY. This enzyme cleaves the COMPLEMENT C3B-bound COMPLEMENT FACTOR B to form C3bBb which is ALTERNATIVE PATHWAY C3 CONVERTASE. Adipsin,C3 Convertase Activator,C3PA Convertase,Factor D,Properdin Factor D,28 kDa Protein, Adipocyte,C3 Proactivator Convertase,C3PAse,Complement Protein D,D Component of Complement,GBGase,Proactivator Convertase,Activator, C3 Convertase,Complement D Component,Convertase Activator, C3,Convertase, C3 Proactivator,Convertase, C3PA,Convertase, Proactivator,Factor D, Complement,Factor D, Properdin,Protein D, Complement
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003170 Complement Pathway, Alternative Complement activation initiated by the interaction of microbial ANTIGENS with COMPLEMENT C3B. When COMPLEMENT FACTOR B binds to the membrane-bound C3b, COMPLEMENT FACTOR D cleaves it to form alternative C3 CONVERTASE (C3BBB) which, stabilized by COMPLEMENT FACTOR P, is able to cleave multiple COMPLEMENT C3 to form alternative C5 CONVERTASE (C3BBB3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX. Alternative Complement Pathway,Properdin Pathway,Alternative Complement Activation Pathway,Complement Activation Pathway, Alternative
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D050606 Mannose-Binding Protein-Associated Serine Proteases Serum serine proteases which participate in COMPLEMENT ACTIVATION. They are activated when complexed with the MANNOSE-BINDING LECTIN, therefore also known as Mannose-binding protein-Associated Serine Proteases (MASPs). They cleave COMPLEMENT C4 and COMPLEMENT C2 to form C4b2a, the CLASSICAL PATHWAY C3 CONVERTASE. MASP,MASP Proteases,MASP-Related Protein,MASPs,MBL-Associated Serine Proteases,MBP-Associated Serine Protease,MBP-Associated Serine Protease-Related Protein,Mannan-Binding Lectin Serine Proteases,Mannose-Binding Protein-Associated Serine Protease,MASP Related Protein,MBL Associated Serine Proteases,MBP Associated Serine Protease,MBP Associated Serine Protease Related Protein,Mannan Binding Lectin Serine Proteases,Mannose Binding Protein Associated Serine Protease,Proteases, MASP,Protein, MASP-Related,Serine Protease, MBP-Associated,Serine Proteases, MBL-Associated
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Manabu Hayashi, and Takeshi Machida, and Yumi Ishida, and Yusuke Ogata, and Tomoko Omori, and Mika Takasumi, and Yuichi Endo, and Toshiyuki Suzuki, and Masayuki Sekimata, and Yoshimi Homma, and Masahito Ikawa, and Hiromasa Ohira, and Teizo Fujita, and Hideharu Sekine
December 2019, Journal of immunology (Baltimore, Md. : 1950),
Manabu Hayashi, and Takeshi Machida, and Yumi Ishida, and Yusuke Ogata, and Tomoko Omori, and Mika Takasumi, and Yuichi Endo, and Toshiyuki Suzuki, and Masayuki Sekimata, and Yoshimi Homma, and Masahito Ikawa, and Hiromasa Ohira, and Teizo Fujita, and Hideharu Sekine
April 2018, Journal of immunology (Baltimore, Md. : 1950),
Manabu Hayashi, and Takeshi Machida, and Yumi Ishida, and Yusuke Ogata, and Tomoko Omori, and Mika Takasumi, and Yuichi Endo, and Toshiyuki Suzuki, and Masayuki Sekimata, and Yoshimi Homma, and Masahito Ikawa, and Hiromasa Ohira, and Teizo Fujita, and Hideharu Sekine
January 2013, Advances in experimental medicine and biology,
Manabu Hayashi, and Takeshi Machida, and Yumi Ishida, and Yusuke Ogata, and Tomoko Omori, and Mika Takasumi, and Yuichi Endo, and Toshiyuki Suzuki, and Masayuki Sekimata, and Yoshimi Homma, and Masahito Ikawa, and Hiromasa Ohira, and Teizo Fujita, and Hideharu Sekine
August 2017, Journal of immunology (Baltimore, Md. : 1950),
Manabu Hayashi, and Takeshi Machida, and Yumi Ishida, and Yusuke Ogata, and Tomoko Omori, and Mika Takasumi, and Yuichi Endo, and Toshiyuki Suzuki, and Masayuki Sekimata, and Yoshimi Homma, and Masahito Ikawa, and Hiromasa Ohira, and Teizo Fujita, and Hideharu Sekine
October 1989, Clinical nephrology,
Manabu Hayashi, and Takeshi Machida, and Yumi Ishida, and Yusuke Ogata, and Tomoko Omori, and Mika Takasumi, and Yuichi Endo, and Toshiyuki Suzuki, and Masayuki Sekimata, and Yoshimi Homma, and Masahito Ikawa, and Hiromasa Ohira, and Teizo Fujita, and Hideharu Sekine
April 2012, The Journal of biological chemistry,
Manabu Hayashi, and Takeshi Machida, and Yumi Ishida, and Yusuke Ogata, and Tomoko Omori, and Mika Takasumi, and Yuichi Endo, and Toshiyuki Suzuki, and Masayuki Sekimata, and Yoshimi Homma, and Masahito Ikawa, and Hiromasa Ohira, and Teizo Fujita, and Hideharu Sekine
June 2014, Journal of immunology (Baltimore, Md. : 1950),
Manabu Hayashi, and Takeshi Machida, and Yumi Ishida, and Yusuke Ogata, and Tomoko Omori, and Mika Takasumi, and Yuichi Endo, and Toshiyuki Suzuki, and Masayuki Sekimata, and Yoshimi Homma, and Masahito Ikawa, and Hiromasa Ohira, and Teizo Fujita, and Hideharu Sekine
January 2007, Advances in experimental medicine and biology,
Manabu Hayashi, and Takeshi Machida, and Yumi Ishida, and Yusuke Ogata, and Tomoko Omori, and Mika Takasumi, and Yuichi Endo, and Toshiyuki Suzuki, and Masayuki Sekimata, and Yoshimi Homma, and Masahito Ikawa, and Hiromasa Ohira, and Teizo Fujita, and Hideharu Sekine
June 2014, Journal of immunology (Baltimore, Md. : 1950),
Manabu Hayashi, and Takeshi Machida, and Yumi Ishida, and Yusuke Ogata, and Tomoko Omori, and Mika Takasumi, and Yuichi Endo, and Toshiyuki Suzuki, and Masayuki Sekimata, and Yoshimi Homma, and Masahito Ikawa, and Hiromasa Ohira, and Teizo Fujita, and Hideharu Sekine
August 2016, Scientific reports,
Copied contents to your clipboard!